Gamelin Erick 4

What Happened

• Erick Gamelin, Chief Development Officer of Acrivon Therapeutics (ACRV), received a grant of derivative securities covering 94,946 shares on March 1, 2026. The reported acquisition price is $0.00, indicating an award/option grant rather than an open‑market purchase; no immediate cash value or sale was reported.

Key Details

• Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (timely).
• Transaction type: Award/Grant of derivative securities (code A on Form 4).
• Shares involved: 94,946 derivative shares granted; acquisition price listed as $0.00.
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Footnote: 25% of the option shares vest on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to continuous service.
• No sale or exercise reported — this is a compensation grant, not a cash transaction.

Context

• This filing reports a grant of derivative awards (likely stock options or restricted stock units) that will vest over about four years. Such grants are typically part of executive compensation and do not by themselves indicate buying or selling sentiment because they are earned over time and subject to service conditions. There was no immediate exercise or sale disclosed in this report.